CXCR4 and Patent ductus arteriosus: The relevance of this immunological view was suggested by preclinical and clinical experiments showing that administering the bicyclam CXCR4 inhibitor AMD3100 to mice and patients with T cell–excluding carcinomas, microsatellite-stable (MSS) pancreatic ductal adenocarcinoma (PDA), and colorectal cancer (CRC) enhanced the intratumoral accumulation of activated T cells (7, 8).